Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-I-ylureido)cyclohexyloxy] benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension

Clinical Science

Volumn 122, Issue 11, 2012, Pages 513-525

  Neckár, Jan ^a,b   Kopkan, Libor ^b,c   Husková, Zuzana ^b,c   Kolář, František ^a,b   Papoušek, František ^a,b   Kramer, Herbert J ^d   Hwang, Sung Hee ^e   Hammock, Bruce D ^e   Imig, John D ^f   Malý, Jiří ^b   Netuka, Ivan ^a   Ošťádal, Bohuslav ^a,b   Červenka, Luděk ^b,c,g  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b Center for Cardiovascular Research   (Czech Republic)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiotensin II; Epoxyeicosatrienoic acid; Hypertension; Kidney; Myocardial ischaemia reperfusion injury; Soluble epoxide hydrolase inhibitor

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CIS 4 [4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY]BENZOIC ACID; DIHYDROXYICOSATRIENOIC ACID; DRINKING WATER; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; 4 (4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; 4-(4-(3-ADAMANTAN-1-YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; BENZOIC ACID DERIVATIVE; CARDIOTONIC AGENT; DRUG DERIVATIVE; ICOSANOID; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HEART FUNCTION; HEART INFARCTION SIZE; HEART PROTECTION; HYPERTENSION; ISCHEMIA; LONG TERM CARE; MALE; NONHUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SYSTOLIC BLOOD PRESSURE; TRANSGENIC RAT; URINARY EXCRETION; ANIMAL; BLOOD PRESSURE; DRUG ANTAGONISM; FEMALE; GENETICS; HEART ARRHYTHMIA; HEART INFARCTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; URINE;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARRHYTHMIAS, CARDIAC; BENZOIC ACIDS; BLOOD PRESSURE; CARDIOTONIC AGENTS; EICOSANOIDS; EPOXIDE HYDROLASES; FEMALE; HYPERTENSION; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; UREA;

EID: 84860233421     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110622     Document Type: Article

References (43)

1. Lloyd-Jones, D. M. (2010) Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 121, 1768-1777.
2. Prisant, L. M. (2005) Hypertensive heart disease. J. Clin. Hypertens. 7, 231-238.
3. Ostadal, B. (2009) The past, the present and the future of experimental research on myocardial ischemia and protection. Pharmacol. Rep. 61, 3-12.
4. Lavu, M., Bhushan, S. and Lefer, D. J. (2010) Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin. Sci. 120, 19-29.
5. Besik, J., Szarszoi, O., Kunes, J., Netuka, I., Maly, J., Kolar, F., Pirk, J. and Ostadal, B. (2007) Tolerance to acute ischemia in adult male and female spontaneously hypertensive rats. Physiol. Res. 56, 267-274.
6. Csonka, C., Kupai, K., Kocsis, G. F., Novak, G., Fekete, V., Bencsik, P., Csont, T. and Ferdinandy, P. (2010) Measurement of myocardial infarct size in preclinical studies. J. Pharmacol. Toxicol. Methods 61, 163-170.
7. Ferdinandy, P., Schulz, R. and Baxter, G. F. (2007) Interaction of cardiovascular risk with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 59, 418-458.
8. Maroko, P. R., Kjekshus, J. K., Sobel, B. E., Watanabe, T., Covell, J. W., Ross, Jr, J. and Braunwald, E. (1971) Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43, 67-82.
9. Nithipatikom, K. and Gross, G. J. (2010) Epoxyeicosatrienoic acids: novel mediators of cardioprotection. J. Cardiovasc. Pharmacol. Ther. 15, 112-119.
10. Fleming, I. and Busse, R. (2006) Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47, 629-633.
11. Imig, J. D. and Hammock, B. D. (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discovery 8, 794-805.
12. Sudhahar, V., Shaws, S. and Imig, J. D. (2010) Epoxyeicosatrienoic acid analogs and vascular function. Curr. Med. Chem. 17, 1181-1190.
13. Certikova Chabova, V., Kramer, H. J., Vaneckova, I., Thumova, M., Skaroupkova, P., Tesar, V., Falck, J. R., Imig, J. D. and Cervenka, L. (2007) The roles of intrarenal 20-hydroxyeicosatetroenoic and epoxyeicosaetraenoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press. Res. 30, 335-346.
14. Certikova Chabova, V., Walkovska, A., Kompanowska-Jezierska, E., Sadowski, J., Kujal, P., Vernerova, Z., Vanourkova, Z., Kopkan, L., Kramer, H. J. and Falck, J. R. (2010) Combined inhibition of 20-hydroxyeicosatetrenoic acid formation and epoxyeicosaetraenoic degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin. Sci. 118, 617-632.
15. Mullins, J. J., Peters, J. and Ganten, D. (1990) Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344, 541-544.
16. Gross, G. J., Gauthier, K. M., Moore, J. M., Falck, J. R., Hammock, B. D., Campbell, W. B. and Nithipatikom, K. (2008) Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 294, H2838-H2844.
17. Gross, G. J., Baker, J. E., Hsu, A., Wu, H. E., Falck, J. R. and Nithipatikom, K. (2010) Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 298, H2201-H2207.
18. Seubert, J. M., Sinal, C. J., Graves, J., DeGraff, L. M., Bradbury, J. A., Lee, C. R., Goralski, K., Carey, M. A., Luria, A., Newman, J. W. et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99, 442-450.
19. Bathu, S. N., Lee, S. B., Qadhi, R. S., Chaudhary, K. R., El-Sikhry, H., Kodela, R., Falck, J. R. and Seubert, J. M. (2011) Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br. J. Pharmacol. 162, 897-907.
20. Hwang, S. H., Tsai, H. J., Liu, J. Y., Morisseau, C. and Hammock, B. D. (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 50, 3825-3840.
21. Honetschlagerova, Z., Huskova, Z., Vanourkova, Z., Sporkova, A., Kramer, H. J., Hwang, S. H., Tsai, H. J., Hammock, B. D., Imig, J. D., Cervenka, L. and Kopkan, L. (2011) Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J. Physiol. 589, 207-219.
22. Kujal, P., Certikova Chabova, V., Vernerova, Z., Walkowska, A., Kompanowska-Jezierska, E., Vanourkova, Z., Huskova, Z., Opocensky, M., Skaroupkova, P., Schejbalova, S. et al. (2010) Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Clin. Exp. Pharmacol. Physiol. 37, 1159-1169.
23. Walkowska, A., Skaroupkova, P., Huskova, Z., Vanourkova, Z., Certiková Chabova, V., Tesar, V., Kramer, H. J., Falck, J. R., Imig, J. D., Kompanowska-Jezierska, E. et al. (2010) Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J. Hypertens. 28, 582-593.
24. Neckar, J., Papousek, F., Novakova, O., Ostadal, B. and Kolar, F. (2002) Cardioprotective effects of chronic hypoxia and preconditioning are not additive. Basic Res. Cardiol. 97, 161-167.
25. Curtis, M. J. and Walker, M. J. (1988) Quantification of arrhythmias using systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. Cardiovasc. Res. 22, 656-665.
26. Asemu, G., Neckar, J., Szarszoi, O., Papousek, F., Ostadal, B. and Kolar, F. (2000) Effects of adaptation to intermittent high altitude hypoxia on ischemic ventricular arrhythmias in rats. Physiol. Res. 49, 597-606.
27. Imig, J. D. (2010) Targeting epoxides for organ damage in hypertension. J. Cardiovasc. Pharmacol. 56, 329-335.
28. Williams, J. M., Murphy, S., Burke, M. and Roman, R. J. (2010) 20-Hydroxyeicosatetraenoic acid: a new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 56, 336-344.
29. Melenovsky, V., Benes, J., Skaroupkova, P., Sedmera, D., Strnad, H., Kolar, M., Vlcek, C., Petrak, J., Benes, Jr, J., Papousek, F. et al. (2011) Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats. Mol. Cell. Biochem. 354, 83-96.
30. Neckar, J., Silhavy, J., Zidek, V., Landa, V., Mlejnek, P., Simakova, M., Seidman, J. G., Seidman, C., Kazdova, L., Klevstig, M. et al. (2011) CD36 overexpression predisposes to arrhythmias but reduces infarct size in spontaneously hypertensive rats: gene expression profile analysis. Physiol. Genomics, doi:10.1152/physiolgenomics.00083.2011.
31. Rakusan, K., Cicutti, N. and Kolar, F. (2001) Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 280, H1407-H1414.
32. Madhun, Z. T., Goldthwait, D. A., McKay, D., Hopfer, U. and Douglas, J. G. (1991) An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J. Clin. Invest. 88, 456-461.
33. Sakairi, Y., Jacobson, H. R., Noland, D. T., Capdevila, J. H., Falck, J. R. and Breyer,M. D. (1995) 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am. J. Physiol. 268, F931-F939.
34. Imig, J. D., Zhao, X., Falck, J. R., Wei, S. and Capdevila, J. H. (2001) Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J. Hypertens. 19, 983-992.
35. Cooley, D. A., Reul, G. J. and Wukasch, D. C. (1972) Ischemic contracture of the heart: 'stone heart'. Am. J. Cardiol. 29, 575-577.
36. Anderson, P. G., Bishop, S. P. and Dignerness, S. B. (1987) Transmural progression of morphological changes during ischemia and reperfusion in the normal and hypertrophied heart. Am. J. Pathol. 129, 152-167.
37. Minor, T., Isselhard, W. and Sturz, J. (1994) Recovery of healthy and hypertrophied hearts after global ischemia and gradual reperfusion. Ann. Cardiol. Angeiol. 43, 395-399.
38. Snoeckx, L. H., van der Vusse, G. J., Coumans, W. A., Willemsen, P. H., van der Nagel, T. and Reneman, R. S. (1986) Myocardial function in normal and spontaneously hypertensive rats during reperfusion after a period of global ischaemia. Cardiovasc. Res. 20, 67-75.
39. Mozaffari, M. S. and Schaffer, S. W. (2003) Effect of hypertension and hypertension-glucose intolerance on myocardial ischemic injury. Hypertension 42, 1042-1049.
40. Saupe, K. W., Lim, C. C., Ingwall, J. S., Apstein, C. S. and Eberli, F. R. (2000) Comparision of hearts with types of pressure-overload left ventricular hypertrophy. Hypertension 35, 1167-1172.
41. Chaudhary, K. R., Abukhashim, M., Hwang, S. H., Hammock, B. D. and Seubert, J. M. (2010) Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyl-oxy]-benzoic acid is protective against ischemia-reperfusion injury. J. Cardiovasc. Pharmacol. 55, 67-73.
42. Gross, E. R., Nithipatikom, K., Hsu, A. K., Peart, J. N., Falck, J. R., Campbell, W. B. and Gross, G. J. (2004) Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J. Mol. Cell. Cardiol. 37, 1245-1249.
43. Nithipatikom, K., Endsley, M. P., Moore, J. M., Isbell, M. A., Falck, J. R., Campbell, W. B. and Gross, G. J. (2006) Effects of selective inhibition of cytochrome P-450 ω-hydroxylases and ischemic preconditioning in myocardial protection. Am. J. Physiol. Heart Circ. Physiol. 290, H500-H505